Takeda Pharmaceutical Co. Ltd.'s oral anaplastic lymphoma kinase (ALK) inhibitor brigatinib has shown progression-free survival (PFS) benefits over close rival crizotinib in the first interim analysis from an ongoing head-to-head trial in the commercially important first-line lung cancer setting.
While the Japanese firm did not disclose details of the top-line findings, it said the first pre-specified interim analysis from...